Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report

Abstract excerpt

Clonal MAPK-pathway activating mutations in the MAP2K1 (MEK1) gene are present in approximately 9% of cutaneous melanomas. These mutations are divided into three classes: RAF-dependent, RAF-regulated, RAF-independent. Cell lines with class-2 or RAF-regulated MAP2K1 -mutations are most responsive to MEK-inhibitors. We present a patient with a class-2 MAP2K1 -mutant stage IV-M1d melanoma who experienced extra- and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to Cutaneous Melanoma Detection and Management
• Share to Melanoma and MAPK Pathways